文章：

新诊断骨髓瘤的四联疗法：三药方案来那度胺、硼替佐米和地塞米松（RVd）与达雷妥尤单抗联合RVD（DRVd）在适合移植患者中的连续队列比较分析

Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients

原文发布日期：2024-09-13

DOI: 10.1038/s41408-024-01120-9

类型: Article

开放获取: 是

英文摘要：

Lenalidomide, bortezomib, and dexamethasone (RVd) have previously been established as standard-of-care induction therapy for newly diagnosed multiple myeloma (NDMM). More recently, randomized phase 3 data have demonstrated the benefit of the addition of daratumumab (Dara-RVd) to the RVd backbone in terms of improved both depth of response and long-term survival benefit as measured by progression-free survival (PFS). Our group has previously published on a historical cohort of 1000 NDMM patients uniformly treated with RVd induction with impressive both PFS and overall survival. Here, we present a comparative analysis of our RVd cohort with a recent cohort of 326 patients induced with Dara-RVd at our institution with intent to transplant. This analysis demonstrates the utility of this regimen in real-world clinical practice and provides additional insights into D-RVd performance in patient subsets often underrepresented in clinical trials, as well as the impact of daratumumab in maintenance for NDMM patients.
 

摘要翻译： 

来那度胺、硼替佐米和地塞米松（RVd）方案此前已被确立为新诊断多发性骨髓瘤（NDMM）的标准诱导治疗方案。近期，随机3期数据显示，在RVd方案基础上联合达雷妥尤单抗（Dara-RVd）能显著提升缓解深度，并通过无进展生存期（PFS）评估获得长期生存获益。我们研究团队曾发表过1000例接受RVd方案诱导治疗的NDMM患者历史队列数据，其PFS和总生存期结果均令人瞩目。本文通过对该RVd队列与本机构近期326例计划移植且接受Dara-RVd诱导治疗患者的队列进行比较分析，证实该方案在真实世界临床实践中的有效性，并为D-RVd方案在临床试验中常未充分代表的患者亚群中的疗效、以及达雷妥尤单抗在NDMM患者维持治疗中的作用提供了新的见解。

原文链接：

Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients